Stay updated on Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page
- Check5 days agoChange DetectedMelanoma-related topics, including MedlinePlus Genetics, were removed from the related topics section. This may reduce quick access to melanoma-specific information and related resources on the study page.SummaryDifference0.2%

- Check13 days agoChange DetectedAdded Melanoma and related topics (MedlinePlus Genetics), Locations (North Carolina), and updated the revision to v3.3.3, while removing HHS Vulnerability Disclosure and North Carolina Locations.SummaryDifference0.4%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRemoved related topics entries for Melanoma and MedlinePlus Genetics from the page. No new core information was added.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.2, affecting only metadata and not the study details. No changes to eligibility, endpoints, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe government funding/operating status notice was removed from the page, while the core study information remains unchanged.SummaryDifference0.4%

- Check56 days agoChange DetectedAdded Melanoma and related topic links (MedlinePlus Genetics) to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.